Fig. 1 · Structure

Documents & Downloads

Empagliflozin

Cat. No. A12440 CAS 864070-44-0
Empagliflozin is a potent, selective sodium glucose co-transporter-2 inhibitor that is in development for the treatment of type 2 diabetes.

In Stock

Publications for Empagliflozin

6 publications citing this product

  1. Yajing Li, .et al. , Eur J Pharmacol, 2026, Jan 10:1010:178375 PMID: 41314453
  2. Danubia Silva Dos Santos, .et al. , Sci Rep, 2023, May 29;13(1):8689 PMID: 37248416
  3. Simone A Melander, .et al. , Eur J Pharmacol, 2023, Jan 5;938:175397 PMID: 36414113
  4. Yu-Jung Heo, .et al. , Biomedicines, 2022, Apr 29;10(5):1032 PMID: 35625768
  5. Nami Lee, .et al. , J Immunol Res, 2021, Jun 2;2021:9944880 PMID: 34124273
  6. CN Koyani, .et al. , Pharmacol Res, 2020, May 17;158:104870 PMID: 32434052

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Empagliflozin inhibits renal glucose reabsorption through SGLT2 blockade. In euglycemic mice given dietary empagliflozin plus an acute dose, fractional glucose reabsorption was 44 ± 3% in wild-type mice and −1 ± 3% in Sglt1−/− mice (mean ± SE), supporting residual SGLT1-mediated transport during SGLT2 inhibition. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
SGLT2 3.1 nM
SGLT5 1.1 μM
SGLT6 2 μM
SGLT1 8.3 μM
SGLT4 11 μM

In Vitro Studies

In neonatal rat ventricular cardiomyocytes, empagliflozin (1 µM, 24 h) shortened action potential duration under normoxia and CoCl2-induced chemical hypoxia. Resting membrane potential and action potential amplitude were unchanged. These cellular findings do not establish antiarrhythmic efficacy in an intact organism. [2]

Direct cardiac NHE1 inhibition should not be assumed. In an isolated rat cardiomyocyte acid-recovery assay, empagliflozin did not significantly inhibit NHE1 flux at 1–10 µM; 30 µM produced only 8% inhibition, compared with >80% for 10 µM cariporide. This result is specific to the tested model and conditions. [3]

Action potentials in neonatal rat cardiomyocytes

Cell-based study · Cultured neonatal Wistar rat ventricular cardiomyocytes under normoxia or CoCl2-induced chemical hypoxia [2]

Empagliflozin shortened beat-rate-corrected APD30, APD50 and APD90 under both conditions. Resting membrane potential and action potential amplitude were unchanged.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Beat-rate-corrected action potential duration at 90% repolarizationmean ± SEM; ms Normoxia, EMPA vs vehicle: 244 ± 4 vs 259 ± 4 ms, P < 0.05; chemical hypoxia: 271 ± 5 vs 292 ± 4 ms, P < 0.01[2]
Resting membrane potential and action potential amplitudereported comparison No difference reported between EMPA and vehicle under either condition[2]

Literature-Reported Treatment Conditions

Treatment concentration
1 µM
Exposure duration
24 h
Method
EMPA exposure after a 4 h, 200 µM CoCl2 challenge where applicable; intracellular microelectrode recordings
Vehicle
DMSO
Reported limits
Final DMSO fraction not identified in the selected methods.
Methods and source locations

Compound reported in the paper: Empagliflozin; Compound label in the paper: EMPA

Applies to the named research compound in this model; does not validate the current Adooq lot, formulation or clinical efficacy.

Methods: Rat neonatal cardiomyocytes isolation and culture; Action potential recordings; Statistical analyses. Results: Empagliflozin reduced action potential duration; Figure 3A–F and caption

Beat-rate-corrected action potential duration at 90% repolarization: Intracellular microelectrodes; unpaired t-test or Mann–Whitney test per figure/methods — Methods: Rat neonatal cardiomyocytes isolation and culture; Action potential recordings; Statistical analyses. Results: Empagliflozin reduced action potential duration; Figure 3A–F and caption

Resting membrane potential and action potential amplitude: Figure 3E–F; no exact values reconstructed from the plots — Methods: Rat neonatal cardiomyocytes isolation and culture; Action potential recordings; Statistical analyses. Results: Empagliflozin reduced action potential duration; Figure 3A–F and caption

Limited NHE1 inhibition in isolated rat cardiomyocytes

Cell-based study · Isolated adult male Sprague-Dawley rat ventricular cardiomyocytes; acid-load recovery in CO2/bicarbonate-free HEPES-buffered Tyrode solution at 37 °C [3]

No significant NHE1 flux inhibition was detected at 1, 3 or 10 µM empagliflozin. At 30 µM, a small significant reduction was reported; cariporide provided a strong positive-control response.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
NHE1-mediated acid extrusion relative to DMSO controlflux–flux regression slope At 1, 3 and 10 µM, slope 95% confidence intervals included 1.0[3]
NHE1 flux at 30 µM EMPA and positive controlreported inhibition; 95% CI 30 µM EMPA: 8% inhibition; slope 95% CI 0.89–0.96. Cariporide 10 µM: >80% inhibition.[3]

Literature-Reported Treatment Conditions

Treatment concentration
1, 3, 10 or 30 µM
Exposure duration
Acute: drug present during the 6 min ammonium pulse and subsequent recovery
Method
cSNARF1 pH imaging after ammonium washout; acid-extrusion flux calculated from recovery rate and buffering capacity
Vehicle
DMSO, 0.01% v/v; 0.03% v/v for 30 µM EMPA
Reported limits
Supplementary chemical-characterization/functional-control figures were not retrieved; main methods and Results 3.1 report them.
Methods and source locations

Compound reported in the paper: Empagliflozin; Compound label in the paper: EMPA

Applies to the named research compound in this model; does not validate the current Adooq lot, formulation or clinical efficacy.

Methods 2.2, 2.3, 2.5, 2.6 and 2.11; Results 3.1; Figures 1 and 2 captions; Figure 2A–F viewed

NHE1-mediated acid extrusion relative to DMSO control: Slope fitted through origin at matched intracellular pH; drug-free control recordings each day — Methods 2.2, 2.3, 2.5, 2.6 and 2.11; Results 3.1; Figures 1 and 2 captions; Figure 2A–F viewed

NHE1 flux at 30 µM EMPA and positive control: Numerical statements from Results 3.1, visually checked against Figure 2; no additional curve-derived decimals — Methods 2.2, 2.3, 2.5, 2.6 and 2.11; Results 3.1; Figures 1 and 2 captions; Figure 2A–F viewed

In Vivo Studies

In male C57BL/6J mice fed CDAHFD, daily oral empagliflozin (10 µg/g for 5 weeks) reduced the reported fibrosis grade from 2.8 ± 0.37 to 1.9 ± 0.33 (mean ± SD) and reduced fibrosis-associated markers relative to vehicle. This model-specific finding does not establish a clinical antifibrotic effect. [4]

Renal glucose reabsorption during SGLT2 inhibition

Animal study · Euglycemic wild-type and Sglt1−/− mice on a low-glucose diet; terminal-anesthesia inulin clearance [1]

After three weeks of dietary empagliflozin, an additional acute dose further reduced fractional glucose reabsorption in both genotypes. Residual reabsorption in wild-type mice was largely absent in Sglt1−/− mice, supporting compensatory SGLT1 transport during SGLT2 inhibition.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Fractional renal glucose reabsorption after dietary treatmentmean ± SE WT: 64 ± 2%; Sglt1−/−: 17 ± 2%; P < 0.001[1]
Fractional renal glucose reabsorption after dietary treatment plus acute dosemean ± SE WT: 44 ± 3%; Sglt1−/−: −1 ± 3%[1]
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
WT, dietary empagliflozin
300 mg/kg of diet
Sglt1−/− on the same diet; comparison with added-dose WTFGR 64 ± 2%[1]
Sglt1−/−, dietary empagliflozin
300 mg/kg of diet
WT on the same dietFGR 17 ± 2%[1]
WT, dietary plus acute empagliflozin
300 mg/kg of diet plus 10 mg/kg intraperitoneally
Dietary-only WT and identically treated Sglt1−/−FGR 44 ± 3%[1]
Sglt1−/−, dietary plus acute empagliflozin
300 mg/kg of diet plus 10 mg/kg intraperitoneally
Dietary-only Sglt1−/− and identically treated WTFGR −1 ± 3%[1]
WT, dietary empagliflozin
Model: Wild-type mice
Route: Dietary
Frequency: Drug-containing diet
Treatment course: 3 weeks
Reported limits: Injection vehicle not specified in selected text; dietary concentration is not a fixed body-weight dose.
Sglt1−/−, dietary empagliflozin
Model: Sglt1−/− mice
Route: Dietary
Frequency: Drug-containing diet
Treatment course: 3 weeks
Reported limits: Injection vehicle not specified in selected text; dietary concentration is not a fixed body-weight dose.
WT, dietary plus acute empagliflozin
Model: Wild-type mice
Route: Dietary plus intraperitoneal
Frequency: Dietary exposure plus one injection
Treatment course: 3 weeks; injection 1 h before clearance
Reported limits: Injection vehicle not specified in selected text; dietary concentration is not a fixed body-weight dose.
Sglt1−/−, dietary plus acute empagliflozin
Model: Sglt1−/− mice
Route: Dietary plus intraperitoneal
Frequency: Dietary exposure plus one injection
Treatment course: 3 weeks; injection 1 h before clearance
Reported limits: Injection vehicle not specified in selected text; dietary concentration is not a fixed body-weight dose.
Methods and source locations

Compound reported in the paper: Empagliflozin; Compound label in the paper: empagliflozin

Applies to the named research compound in this model; does not validate the current Adooq lot, formulation or clinical efficacy.

Methods: Animals and acute/chronic glucosuric responses; Results: SGLT2 inhibitor reduces renal FGR; Figure 3A–D and caption

Fractional renal glucose reabsorption after dietary treatment: Filtered glucose from plasma glucose × [3H]inulin clearance; reabsorption from filtered minus urinary glucose — Methods: Animals and acute/chronic glucosuric responses; Results: SGLT2 inhibitor reduces renal FGR; Figure 3A–D and caption

Fractional renal glucose reabsorption after dietary treatment plus acute dose: Same clearance design; negative mean is retained as reported and is consistent with near-zero net reabsorption — Methods: Animals and acute/chronic glucosuric responses; Results: SGLT2 inhibitor reduces renal FGR; Figure 3A–D and caption

WT, dietary empagliflozin · Methods: Animals and acute/chronic glucosuric responses; Results: SGLT2 inhibitor reduces renal FGR; Figure 3A–D and caption

Sglt1−/−, dietary empagliflozin · Methods: Animals and acute/chronic glucosuric responses; Results: SGLT2 inhibitor reduces renal FGR; Figure 3A–D and caption

WT, dietary plus acute empagliflozin · Methods: Animals and acute/chronic glucosuric responses; Results: SGLT2 inhibitor reduces renal FGR; Figure 3A–D and caption

Sglt1−/−, dietary plus acute empagliflozin · Methods: Animals and acute/chronic glucosuric responses; Results: SGLT2 inhibitor reduces renal FGR; Figure 3A–D and caption

Hepatic fibrosis in diet-fed mice

Animal study · Male C57BL/6J mice fed a choline-deficient, L-amino acid-defined, high-fat diet (CDAHFD) [4]

Empagliflozin reduced the reported histological fibrosis grade and fibrosis-associated markers relative to vehicle-treated CDAHFD mice. Fibrosis remained detectable.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Sirius-Red-based liver fibrosis gradereported mean ± SD CDAHFD/vehicle: 2.8 ± 0.37; CDAHFD/EMPA: 1.9 ± 0.33[4]
Fibrosis-associated protein and transcript expressiondirection relative to CDAHFD/vehicle Reduced α-SMA, fibronectin and cTGF proteins; reduced α-SMA, collagen 1α1, TGF-β and MMP2 transcripts[4]

Conditions shared by the study groups

Route
Oral gavage
Frequency
Daily
Treatment course
5 weeks of EMPA; CDAHFD for 7 weeks per Results 3.1
Vehicle
Dimethyl sulfoxide (vehicle group)
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
CDAHFD plus empagliflozin
10 µg/g per day
CDAHFD/vehicle and control-diet/vehicle groups, n=8 allocated per groupLower reported fibrosis grade and fibrosis-associated markers than CDAHFD/vehicle[4]
CDAHFD plus empagliflozin
Model: Male C57BL/6J mice; n=8 allocated to each of three groups
Reported limits: Final DMSO concentration and endpoint-specific analyzed n not identified in selected text.
Methods and source locations

Compound reported in the paper: Empagliflozin; Compound label in the paper: EMPA

Applies to the named research compound in this model; does not validate the current Adooq lot, formulation or clinical efficacy.

Methods 2.1, 2.3–2.5 and 2.7; Results 3.1; Figure 1A–D and caption

Sirius-Red-based liver fibrosis grade: Histological grading; values from Results 3.1, direction checked in Figure 1b — Methods 2.1, 2.3–2.5 and 2.7; Results 3.1; Figure 1A–D and caption

Fibrosis-associated protein and transcript expression: Western blot with β-actin loading control and qRT-PCR with GAPDH reference; Figure 1c–d; no fold values inferred — Methods 2.1, 2.3–2.5 and 2.7; Results 3.1; Figure 1A–D and caption

CDAHFD plus empagliflozin · Methods 2.1, 2.3–2.5 and 2.7; Results 3.1; Figure 1A–D and caption

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 864070-44-0
Formula C23H27ClO7
Molecular Weight 450.91
SMILES
C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 88 mg/mL (195.15 mM)
Water Insoluble
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
14 mg/mL
Vehicle
15% Captisol

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Rieg T, Masuda T, Gerasimova M, et al. Increase in SGLT1-mediated transport explains renal glucose reabsorption during genetic and pharmacological SGLT2 inhibition in euglycemia American journal of physiology. Renal physiology (2014). PMID: 24226519 DOI: 10.1152/ajprenal.00518.2013 Source material
  2. [2] Silva Dos Santos D, Turaça LT, Coutinho KCDS, et al. Empagliflozin reduces arrhythmogenic effects in rat neonatal and human iPSC-derived cardiomyocytes and improves cytosolic calcium handling at least partially independent of NHE1 Scientific reports (2023). PMID: 37248416 DOI: 10.1038/s41598-023-35944-5 Source material
  3. [3] Chung YJ, Park KC, Tokar S, et al. Off-target effects of sodium-glucose co-transporter 2 blockers: empagliflozin does not inhibit Na+/H+ exchanger-1 or lower [Na+]i in the heart Cardiovascular research (2021). PMID: 33135077 DOI: 10.1093/cvr/cvaa323 Source material
  4. [4] Heo YJ, Lee N, Choi SE, et al. Empagliflozin Reduces the Progression of Hepatic Fibrosis in a Mouse Model and Inhibits the Activation of Hepatic Stellate Cells via the Hippo Signalling Pathway Biomedicines (2022). PMID: 35625768 DOI: 10.3390/biomedicines10051032 Source material

Publications

6 publications citing this product

  1. Yajing Li, .et al. , Eur J Pharmacol, 2026, Jan 10:1010:178375 PMID: 41314453
  2. Danubia Silva Dos Santos, .et al. , Sci Rep, 2023, May 29;13(1):8689 PMID: 37248416
  3. Simone A Melander, .et al. , Eur J Pharmacol, 2023, Jan 5;938:175397 PMID: 36414113
  4. Yu-Jung Heo, .et al. , Biomedicines, 2022, Apr 29;10(5):1032 PMID: 35625768
  5. Nami Lee, .et al. , J Immunol Res, 2021, Jun 2;2021:9944880 PMID: 34124273
  6. CN Koyani, .et al. , Pharmacol Res, 2020, May 17;158:104870 PMID: 32434052

Added to your cart

View Cart Checkout
Loading...